Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19Urinary Bladder Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer, Hereditary, 7 1Nonseminomatous germ cell tumor 1Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Adenocarcinoma 1

Interventions

pembrolizumab 44Gemcitabine 23enfortumab vedotin 21Nivolumab 20Cisplatin 17avelumab 16Magnetic Resonance Spectroscopy 15Carboplatin 14atezolizumab 13Specimen Handling 12Docetaxel 11sacituzumab govitecan 9Paclitaxel 8Ipilimumab 8durvalumab 6Mitomycin 5Fluorodeoxyglucose F18 5cabozantinib 4Taxes 4toripalimab 3pemigatinib 3erdafitinib 3X-Rays 3Radiosurgery 3Platinum 3Pemetrexed 3Immunoglobulin G 3CTLA-4 Antigen 3Biopsy 3ALT-803 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × cabazitaxel × 1 year × Clear all
NCT01616875 2026-03-06

Bristol Bladder Trial

University Hospitals Bristol and Weston NHS Foundation Trust

Phase 2 Completed
28 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡